Safety and Efficacy of IBI306 in HeFH Patients

Innovent Biologics

Status and phase

Completed

Phase 3

Conditions

Heterozygous Familial Hypercholesterolemia

Treatments

Drug: placebo

Drug: IBI306

Study type

Interventional

Funder types

Industry

Identifiers

NCT04179669

CIBI306C301

Details and patient eligibility

About

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol (LDL-C) uptake. In the phase I study, IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the efficacy and safety of a novel PCSK-9 anti-body, IBI306, in Chinese patients with heterozygous familial hypercholesterolemia.

Full description

The study plans to enroll 148 patients with heterozygous familial hypercholesterolemia. Subjects will maintain a low-fat diet and stable current lipid-lowering therapy for at least 4 weeks and will be randomized into different dose groups at a 1:1 ratio, followed by a 2:1 randomization double-blind treatment with subcutaneous IBI306 150 mg (n=49) or placebo (n=25) every two weeks; or subcutaneous injection of IBI306 450mg (n=49) or placebo (n=25) every four weeks. Treatment lasts for 12 weeks. After 12 weeks, each group enters a 12-week open-label treatment, in which IBI306 subjects continue to receive IBI306, and placebo subjects shift to receive IBI306. The primary endpoint is the percent change in LDL-C levels relative to baseline at 12 weeks. Secondary endpoints include changes in baseline lipid levels, drug safety, and immunogenicity at 12 weeks and 24 weeks. The exploratory endpoint is the population pharmacokinetic profile of IBI306 in Chinese subjects with heterozygous familial hypercholesterolemia. If necessary, the dose of IBI306 will be adjusted accordingly based on the results of the ongoing multi-dose escalation study. After the open period, the subjects will be given a safety visit for 8 weeks.

Enrollment

149 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Subjects must meet all of the following inclusion criteria in order to be included in the study:

Provide a signed and dated informed consent form
Men or women 18 to 70 years of age at screening
Weight ≥ 40 kg during screening
Confirmed diagnosis of heterozygous familial hypercholesterolemia
Maintain a low-fat diet and stabilize the current lipid-lowering therapy

Exclusion criteria

• Subjects who do not meet any of the following exclusion criteria cannot be included in the study:

Patients diagnosed as homozygous familial hypercholesterolemia
Dialysis or plasmapheresis performed within 4 months prior to screening
History of liver transplant
Subjects adjusted for treatment of statins, ezetimibe, niacin, omega-fatty acids within 4 weeks prior to screening
New York Heart Association (NYHA) grade III or IV heart failure, or recent detection of left ventricular ejection fraction ≤ 30%
Have serious cardiovascular, cerebrovascular, liver and kidney related diseases